Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | MicrobiomeTrials
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-02-27Est. Completion: 2026-11
Enrollment target: 110 participants
Locations
Mayo Clinic - Arizona, Phoenix, Arizona, United States
The University of Arizona Cancer Center, Tucson, Arizona, United States
St. Bernards Medical Center, Jonesboro, Arkansas, United States
Highlands Oncology Group, Springdale, Arkansas, United States
Pacific Cancer Medical Center, Anaheim, California, United States
Comprehensive Blood and Cancer Center - Bakersfield, Bakersfield, California, United States
Orange Coast Memorial Medical Center, Fountain Valley, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Norris Comprehensive Cancer Center, Los Angeles, California, United States
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
Sharp Memorial Hospital, San Diego, California, United States
Torrance Memorial Physician Network - Cancer Care and Infusion Center, Torrance, California, United States
PIH Health, Whittier, California, United States
Memorial Cancer Institute, Hollywood, Florida, United States
Mayo Clinic - Florida, Jacksonville, Florida, United States
Other microbiome trials you might be interested in